IART
Integra LifeSciences Holdings Corporation
$15.13
+$0.29(+1.95%)
49
Overall
60
Value
45
Tech
44
Quality
Market Cap
$1.15B
Volume
1.19M
52W Range
$11.06 - $27.13
Target Price
$17.22
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $882.7M | $992.1M | $1.2B | $1.5B | $1.5B | $1.4B | $1.5B | $1.6B | $1.5B | $1.6B | ||
| Total Revenue | $882.7M | $992.1M | $1.2B | $1.5B | $1.5B | $1.4B | $1.5B | $1.6B | $1.5B | $1.6B | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $-326.5M | $-349.1M | $-435.5M | $-571.5M | $564.7M | $520.8M | $597.8M | $587.4M | $656.8M | $728.5M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $556.2M | $643.0M | $752.7M | $900.9M | $952.9M | $851.0M | $944.6M | $970.3M | $884.7M | $882.1M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $476.6M | $527.6M | $707.9M | $789.9M | $859.1M | $699.7M | $747.4M | $731.4M | $773.2M | $853.6M | ||
| Research & Development | $50.9M | $58.2M | $63.5M | $78.0M | $144.5M | $77.4M | $93.1M | $101.2M | $104.2M | $115.4M | ||
| Research Expense | $50.9M | $58.2M | $63.5M | $78.0M | $144.5M | $77.4M | $93.1M | $101.2M | $104.2M | $115.4M | ||
| Selling, General & Administrative | $415.8M | $455.6M | $624.1M | $690.7M | $687.6M | $594.5M | $637.4M | $616.3M | $656.6M | $717.0M | ||
| Selling & Marketing Expenses | $415.8M | $455.6M | $624.1M | $690.7M | -- | -- | -- | -- | -- | -- | ||
| General & Administrative Expenses | $-10.1M | $-10.3M | $-12.9M | $-16.3M | $687.6M | $594.5M | $637.4M | $616.3M | $656.6M | $717.0M | ||
| Salaries & Wages | $-15.4M | $-17.3M | $-21.6M | $-20.8M | $-9.4M | $-6.2M | $-13.8M | -- | -- | -- | ||
| Depreciation & Amortization | $10.0M | $13.9M | $20.4M | $21.2M | $27.0M | $27.8M | $16.9M | $13.9M | $12.4M | $21.3M | ||
| Depreciation & Amortization | $10.0M | $13.9M | $20.4M | $21.2M | $27.0M | $27.8M | $16.9M | $13.9M | $12.4M | $21.3M | ||
| Amortization | $10.0M | $13.9M | $20.4M | $21.2M | $27.0M | $27.8M | $16.9M | $13.9M | $12.4M | $21.3M | ||
| Other Operating Expenses | -- | $-400.0K | $-2.0M | $-762.0K | $-12.2M | -- | $-5.0M | -- | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $79.6M | $115.3M | $44.8M | $111.0M | $93.8M | $151.4M | $197.2M | $238.9M | $111.5M | $28.4M | ||
| EBITDA | $132.6M | $177.0M | $105.8M | $180.8M | $220.4M | $281.1M | $384.9M | $381.8M | $256.0M | $193.3M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $23.5M | $25.8M | $35.0M | $64.7M | $54.0M | $71.6M | $50.4M | $49.6M | $51.4M | $70.6M | ||
| Intinc | $30.0K | $24.0K | $255.0K | $2.8M | $10.8M | $9.3M | $6.7M | $11.9M | $17.2M | $20.0M | ||
| Net Non-Operating Interest Income/Expense | $-23.5M | $-25.8M | $-34.8M | $-61.9M | $-43.2M | $-62.3M | $-43.7M | $-37.7M | $-34.2M | $-50.6M | ||
| Gain on Sale of Securities | -- | -- | $3.0M | -- | -- | -- | $455.0K | -- | -- | -- | ||
| Other Income/Expense | $-4.6M | $-845.0K | $-1.3M | $-8.3M | $-9.5M | $-4.4M | $-61.1M | $-12.7M | $-3.7M | $-3.9M | ||
| Other Special Charges | $4.6M | $845.0K | $1.3M | $8.3M | $9.5M | $4.4M | $19.3M | $12.0M | $3.7M | $3.9M | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | $-10.7M | $-27.5M | $-81.7M | -- | -- | -- | $-336.0K | -- | -- | -- | ||
| Special Income Charges | $10.7M | $27.5M | $87.9M | $4.9M | $-5.8M | -- | $336.0K | -- | -- | -- | ||
| Impairment of Capital Assets | -- | -- | $-3.3M | $-4.9M | $5.8M | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $71.5M | $101.8M | $14.1M | $63.8M | $111.0M | $165.1M | $265.1M | $263.5M | $132.4M | $52.4M | ||
| Pre-Tax Income | $60.7M | $90.4M | $11.4M | $57.4M | $60.1M | $93.5M | $214.7M | $213.9M | $81.1M | $-18.2M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $53.8M | $15.8M | $-53.4M | $-3.4M | $9.9M | $-40.4M | $45.6M | $33.3M | $13.3M | $-11.3M | ||
| NET INCOME | ||||||||||||
| Net Income | $6.9M | $74.6M | $64.7M | $60.8M | $50.2M | $133.9M | $169.1M | $180.6M | $67.7M | $-6.9M | ||
| Net Income (Continuing Operations) | $6.9M | $74.6M | $64.7M | $60.8M | $50.2M | $133.9M | $169.1M | $180.6M | $67.7M | $-6.9M | ||
| Net Income (Discontinued Operations) | $6.9M | $74.6M | $64.7M | $60.8M | $50.2M | $133.9M | $169.1M | $180.6M | $67.7M | $-6.9M | ||
| Net Income (Common Stockholders) | $6.9M | $74.6M | $64.7M | $60.8M | $50.2M | $133.9M | $169.1M | $180.6M | $67.7M | $-6.9M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-29.5M | ||
| TOTALS | ||||||||||||
| Total Expenses | $150.1M | $178.6M | $272.4M | $218.5M | $1.4B | $1.2B | $1.3B | $1.3B | $1.4B | $1.6B | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $69.0M | $148.8M | $76.9M | $82.9M | $85.6M | $84.7M | $84.7M | $83.0M | $80.1M | $77.0M | ||
| Average Shares Outstanding (Diluted) | $71.4M | $158.4M | $79.1M | $84.0M | $86.5M | $85.2M | $85.5M | $83.5M | $80.3M | $77.0M | ||
| Shares Outstanding | $74.0M | $149.6M | $78.5M | $85.2M | $84.4M | $84.4M | $83.2M | $81.6M | $78.2M | $77.2M | ||
| Basic EPS | $0.21 | $0.50 | $0.84 | $0.73 | $0.59 | $1.58 | $2 | $2.18 | $0.85 | $-0.09 | ||
| Basic EPS (Continuing Operations) | $0.10 | $0.50 | $0.84 | -- | $0.59 | $1.58 | $2 | $2.18 | $0.85 | $-0.09 | ||
| Diluted EPS | $0.20 | $0.47 | $0.82 | $0.72 | $0.58 | $1.57 | $1.98 | $2.16 | $0.84 | $-0.09 | ||
| Diluted EPS (Continuing Operations) | $0.10 | $0.47 | $0.82 | -- | $0.58 | $1.57 | $1.98 | $2.16 | $0.84 | $-0.09 | ||
| OTHER METRICS | ||||||||||||
| Basic Discontinuous Operations | $-0.15 | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Diluted Discontinuous Operations | $-0.15 | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Gain On Sale Of Business | -- | -- | -- | -- | -- | -- | $41.8M | $644.0K | -- | -- | ||
| Interest Expense Operating | $-12.7M | $-14.4M | $-32.3M | $-58.3M | $-3.1M | $-2.3M | $-1.2M | -- | -- | -- | ||
| Net Income Discontinuous Operations | $-10.4M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $-10.1M | $-10.3M | $-12.9M | $-16.3M | $687.6M | $594.5M | $637.4M | $616.3M | $656.6M | $717.0M | ||
| Rent And Landing Fees | $-10.1M | $-10.3M | $-12.9M | $-16.3M | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | $415.8M | $455.6M | $624.1M | $690.7M | -- | -- | -- | -- | -- | -- | ||
| Write Down | -- | -- | $-2.9M | -- | -- | -- | -- | -- | -- | -- | ||
| Restruct | $-10.7M | $-27.5M | $-81.7M | -- | -- | -- | $-336.0K | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | IART | $15.13 | +2.0% | 1.19M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Integra LifeSciences Holdings Corporation Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW